Title : Asciminib and ponatinib exert synergistic anti-neoplastic effects on CML cells expressing BCR-ABL1 T315I-compound mutations.

Pub. Date : 2021

PMID : 34659899






3 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 We demonstrate that asciminib synergizes with ponatinib in inducing growth-arrest and apoptosis in patient-derived CML cell lines and murine Ba/F3 cells harboring BCR-ABL1 T315I or T315I-including compound mutations. ponatinib c-abl oncogene 1, non-receptor tyrosine kinase Mus musculus
2 Asciminib and ponatinib also produced cooperative effects on CRKL phosphorylation in BCR-ABL1-transformed cells. ponatinib c-abl oncogene 1, non-receptor tyrosine kinase Mus musculus
3 The growth-inhibitory effects of the drug combination "asciminib+ponatinib" was further enhanced by hydroxyurea (HU), a drug which has lately been described to suppresses the proliferation of BCR-ABL1 T315I+ CML cells. ponatinib c-abl oncogene 1, non-receptor tyrosine kinase Mus musculus